Evaluación y clasificación de los pacientes con lesión e infarto de miocardio

REFERENCIAS
1 Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J 2012; 33:2551–67.
2 Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess IAMprovement in therapeutic outcomes by optIAMizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009; 119:2758–64.
3 Bonaca MP, Wiviott SD, Braunwald E, et al. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIAMI 38 trial. Circulation 2012;125:577–83.
4 White HD, Reynolds HR, Carvalho AC, et al. Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: Results from long-term follow-up of the occluded artery trial (OAT) cohort. Am Heart J 2012;163:563–71.
5 Collinson PO. Type 2 myocardial infarction. Heart 2015; 101:89–90.
6 Shah AS, McAllister DA, Mills R, et al. Sensitive troponin assay and the classification of myocardial infarction. Am J Med 2015; 128:493–501.e3.
7 Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58:1574–81.
8 Shah ASV, Griffiths M, Lee KK, et al. High sensitivity cardiac troponin and the
under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ
2015;350:g7873–3.
9 Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012; 58:54–61.
10 Collinson PO, Hammerer-Lercher A, Suvisaari J, et al. How well do laboratories adhere to recommended clinical guidelines for the management of myocardial infarction: the cardiac marker guideline uptake in Europe (CARMAGUE) study. Clin Chem 2016; 62:1264–71.
11 Mills NL, Churchhouse AMD, Lee KK, et al. IAMplementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA 2011;305:1210–16.
12 Body R, Carley S, McDowell G, et al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol 2011; 58:1332–9.
13 Rubini-GIAMenez M, Hoeller R, Reichlin T, et al. Rapid rule out of acute myocardial infarction using undetectable levels of high-sensitivity cardiac troponin. Int J Cardio 2013;168:3896–901.
14 Neumann JT, Sörensen NA, Schwemer T, et al. Diagnosis of myocardial infarction using a high-sensitivity troponin i 1-hour algorithm. JAMA Cardiol
2016; 1:397–404.
15 Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37:267–315.
16 Shah ASV, Anand A, Sandoval Y, et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet 2015; 386:2481–8.
17 Shah ASV, Anand A, Chapman AR, et al. Measurement of cardiac troponin for exclusion of myocardial infarction—Authors’ reply. Lancet 2016; 387:2289–91.
18 Alpert JS, Thygesen KA. The Case for a Revised Definition of Myocardial Infarction —The Ongoing Conundrum of Type 2 Myocardial Infarction vs Myocardial Injury.JAMA Cardiol 2016;1:249–50.
19 Alpert JS, Thygesen KA, White HD, et al. Diagnostic and therapeutic IAMplications of type 2 myocardial infarction: review and commentary. Am J Med 2014; 127:105–8.
20 Sandoval Y, Smith SW, Thordsen SE, et al. Supply/demand type 2 myocardial infarction: Should we be paying more attention? J Am Coll Cardiol 2014;63:2079–87.
21 White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischaemia as well as necrosis? J Am Coll Cardiol 2011; 57:2406–8.
22 Wang W, Schulze CJ, Suarez-Pinzon WL, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106:1543–9.
23 Hessel MHM, Atsma DE, van der Valk EJM, et al. Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stIAMulation. Pflugers Arch 2008; 455:979–86.
24 Sabatine MS, Morrow DA, de Lemos JA, et al. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIAMI 35. Eur Heart J 2009;30:162–9.
25 Chin CWL, Shah ASV, McAllister DA, et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J 2014; 35:2312–21.
26 Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012; 33:2252–7.
27 Shah AS, Newby DE, Mills NL. High sensitivity cardiac troponin in patients with chest pain. BMJ 2013; 347:f4222.
28 Melanson SE, Conrad MJ, Mosammaparast N, et al. IAMplementation of a highly sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of results. Clin ChIAM Acta 2008; 395:57–61.
29 Makam AN, Nguyen OK. Use of cardiac biomarker testing in the emergency department. JAMA Intern Med 2015; 175:67–75.
30 Baron T, Hambraeus K, Sundstrom J, et al. Type 2 myocardial infarction in clinical practice. Heart 2015; 101:101–6.
31 Javed U, Aftab W, Ambrose JA, et al. Frequency of elevated troponin I and diagnosis of acute myocardial infarction. Am J Cardiol 2009; 104:9–13.
32 El-Haddad H, Robinson E, Swett K, et al. Prognostic IAMplications of type 2 myocardial infarctions. World J Cardiovasc Dis 2012; 2:237–41.
33 Saaby L, Poulsen TS, Hosbond S, et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med 2013;126:789–97.
34 Szymański FM, Karpiński G, Płatek AE, et al. Clinical characteristics, aetiology and occurrence of type 2 acute myocardial infarction. Kardiol Pol 2014; 72:339–44.
35 Stein GY, Herscovici G, Korenfeld R, et al. Type-II myocardial infarction--patient characteristics, management and outcomes. PLoS ONE 2014;9: e84285.
36 Melberg T, Burman R, Dickstein K. The IAMpact of the 2007 ESCACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: a retrospective cohort study. Int J Cardiol 2010; 139:228–33.
37 Sandoval Y, Thordsen SE, Smith SW, et al. Cardiac troponin changes to distinguish type 1 and type 2 myocardial infarction and 180-day mortality risk. Eur Heart J: Acute Cardiovasc Care 2014;3:317–25.
38 Smith SW, Pearce LA, Murakami MM, et al. Diagnosis of type I versus type II myocardial infarction in emergency department patients with ischemic symptoms. Ann Emerg Med 2011;58:S211–12.
39 Smith SW, Diercks DB, Nagurney JT, et al. Central versus local adjudication of myocardial infarction in a cardiac biomarker trial. Am Heart J 2013; 165:273–9.
40 Bonaca MP, Ruff CT, Kosowsky J, et al. Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIAMI ED Chest Pain Study. Eur Heart J Acute Cardiovasc Care 2013; 2:195–202.
41 Sarkisian L, Saaby L, Poulsen TS, et al. Clinical Characteristics and Outcomes of Patients with Myocardial Infarction, Myocardial Injury, and Nonelevated Troponins. Am J Med 2016; 129:446.e5–21.
42 Chapman AR, Shah AS, Anand A, et al. Long term outcomes of patients with type 2 myocardial infarction and myocardial injury. Eur Heart J 2016; 37(Suppl 1):987.